igf 1 lr3 canada IGF-1 IGF1 LR3 | IGF1 Peptide

Firstly, the Xc system (solute carrier family 7 member 11 and family 3 member 2 (SLC7A11 and SLC3A2)) is responsible for taking up cystine to generate the substrate cysteine for the synthesis of GSH and is also involved in the formation of the GPX4 catalytic unit

mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation

The result is synergistic -- 2-3x greater GH output than either alone (Bowers et al., 1991)

Res., vol

Retrieved from ScienceDirect